Remdesivir-associated bradycardia in COVID-19: a rapid review protocol.

ABSTRACT:

Introduction

Remdesivir is an antiviral medication that is used in the treatment of severe COVID-19. Research has highlighted the potential cardiac side effects of remdesivir, including the occurrence of remdesivir-associated bradycardia (RAB), but these findings have not been consistent. In addition, very little is known about the clinical implications and outcomes of RAB. The aim of this rapid systematic review is to determine the event rate of developing bradycardia while receiving remdesivir treatment compared with not receiving remdesivir in patients diagnosed with COVID-19.

Methods and analysis

This study follows the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocol guidelines and will include original papers related to COVID-19, remdesivir and

SUBMITTER: Tian E 

PROVIDER: S-EPMC10254952 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature